Santa Clara-based Autonomous Healthcare has landed a coveted U.S. Food and Drug Administration De Novo marketing authorization for its SyncronE software, carving out a brand-new device category for ventilator waveform analysis and making SyncronE the first product in that class. The move clears hospitals to roll out an automated system that checks pressure and flow waveforms on every breath and flags ineffective efforts, patient breaths the ventilator does not support, a problem that can easily slip past busy bedside teams. The company says it is now shifting from regulatory slog to day-to-day clinical deployment.
FDA decision and a new device class
The FDA De Novo database shows the agency granted the De Novo request for SyncronE (DEN250025) with a Decision Date of June 18, classifying the product as ventilator waveform analysis software. That classification lets SyncronE be marketed as a Class II medical device in the United States and sets the regulatory template future waveform-analysis tools will have to follow. The listing also names Autonomous Healthcare as the requester and records the company’s Santa Clara address.
Company reaction
In a press release via PR Newswire, Autonomous Healthcare CEO Behnood Gholami called the De Novo authorization a milestone years in the making and said the company took the harder path by pushing to create an entirely new device category. Chief Medical Officer James M. Bailey added, "Recognition is the first step in managing any clinical problem," and the firm said SyncronE is intended to help respiratory therapists spot asynchrony that often goes unnoticed at the bedside.
How SyncronE works and who it's for
Per the Autonomous Healthcare product page, SyncronE reviews previously recorded ventilator pressure and flow waveforms and summarizes its findings breath by breath for a respiratory therapist to interpret. The product page describes the software as an adjunctive aid for respiratory therapists caring for adult patients 22 years of age and older who are receiving invasive mechanical ventilation, and notes that it is not intended for time-sensitive decision-making. Company materials and the product page also caution that federal law limits SyncronE’s sale to sale by or on the order of a physician.
Why waveform analysis matters
Patient-ventilator asynchrony is common and has been linked to longer durations of mechanical ventilation and higher ICU mortality. Systematic reviews report asynchrony at rates that can affect a large share of ventilated patients, according to a review in the Journal of Intensive Care. Ineffective efforts, when a patient’s inspiratory effort fails to trigger ventilator support, are among the most frequent forms of asynchrony and have been associated with diaphragm injury and difficulty weaning. That backdrop has fueled efforts by companies and hospitals to automate waveform review instead of relying solely on intermittent bedside checks.
What the evidence shows
A 2020 validation study comparing SyncronE’s waveform analysis with clinician visual review found that the automated system had substantially higher sensitivity, at about 83 percent versus roughly 41 percent for clinicians, when both were benchmarked against diaphragm or esophageal pressure references (Phan et al., Journal of Clinical Monitoring and Computing, 2020). The company also cites multisite performance data and a pilot study listed at ClinicalTrials.gov (NCT04550871) in which SyncronE tablets monitored patients while clinicians were blinded to the device output. Those validation data contributed to the evidence the agency evaluated in reaching its De Novo decision.
What hospitals and respiratory therapists should expect
Hospitals that adopt SyncronE will need to plug the software into existing charting and quality-improvement workflows and train respiratory care teams to review flagged events and adjust ventilator settings when appropriate. Because SyncronE works on stored waveforms rather than acting as a closed-loop controller, early use is likely to center on quality initiatives and decision support instead of automated ventilator control, the company’s materials indicate (Autonomous Healthcare).
Regulatory note
The FDA De Novo listing sets the classification and special controls for ventilator waveform analysis software but does not replace other statutory or regulatory obligations that hospitals, clinicians, and manufacturers must meet. The company also reiterated that federal law restricts SyncronE’s sale to sale by or on the order of a physician, as noted in its release via PR Newswire.
